CNS & neurology

Neurological programs, delivery barriers and the relationship between biomarkers and patient outcomes.

ClarusBIOTECH REVIEWEvidence & developmentHypothetical consulting case

Leqembi’s randomized evidence and AMT-130’s September update frame a client’s sensitivity analysis and evidence reserve.

3 min read · 2 cited sources

ClarusBIOTECH REVIEWValue Inflection EngineeringEvidence synthesis · white paper

A practical architecture for communicating clinical meaning, financing exposure and the work required for adoption.

4 min read · 3 cited sources

ClarusBIOTECH REVIEWEvidence & developmentHistorical case analysis

APOLLO joined a molecular mechanism to 18-month clinical measures in a defined hereditary disease.

2 min read